Specialty Connect
* This Program is Sold Out *
Specialty Connect: Focus on Hemophilia
Monday, April 23 | Noon – 5:45 pm
The Westin Boston Waterfront Hotel
Lunch in Harbor Ballroom I (12:00pm-1:00pm)
Program in Harbor Ballroom II and III (1:00pm-5:45pm)
Hemophilia is an inherited bleeding disorder caused by mutations in the factor VIII clotting gene (hemophilia A) or factor IX clotting gene (hemophilia B). Defects in clot formation lead to recurrent spontaneous bleeds into soft tissue, joints and muscles, ultimately resulting in severe disabilities and early death. Advances in diagnosis and treatment over the past 20 years have transformed hemophilia from a fatal condition to a manageable chronic disease. Yet despite affecting only about 20,000 people, it ranks as one of the most expensive chronic diseases in the United States, with treatment costs as high as $1 million per year for patients who develop complications.
Given the significant clinical and economic complexities surrounding the treatment of hemophilia, it is imperative that managed care professionals understand the disease state, evolving standards of care and emerging therapeutic options. Specialty Connect 2018 is designed for industry leaders, experts and managed care pharmacists operating in the fast-growing specialty sector. This year’s program will provide a thorough immersion in the concepts most important to quality hemophilia management and offer ample opportunities for networking with like-minded colleagues.
Ensuring optimal cost-effective care in hemophilia has never been more important. You can’t afford to miss this dynamic, cutting-edge program!
Note: Registration for Specialty Connect is separate from the AMCP Annual Meeting 2018. Registration Fees: $225 Advance / $250 Onsite
* This Program is Sold Out *
Program Agenda
Please note that programming is still under development and timing may adjust slightly.
12:00 pm to 1:00 pm Lunch and Networking
1:00 pm to 1:15 pm Welcome and Introductions
1:15 pm to 2:15 pm Didactic Presentation – The Present and Future of Hemophilia Treatment
2:15 pm to 2:25 pm Break
2:25 pm to 3:25 pm Didactic Presentation – Managing Patients with Hemophilia: A Payer’s Perspective
3:25 pm to 3:40 pm Break
3:40 pm to 4:25 pm Didactic Presentation – Gene Therapy for Hemophilia: Hope for a Cure?
4:25 pm to 4:35 pm Break
4:35 pm to 5:35 pm Panel Discussion – Perspectives in Hemophilia Management
5:35 pm to 5:45 pm Closing Remarks
6:00 pm – 8:00 pm Satellite Symposium: Managing Multiple Sclerosis: Current Treatment and Care Management Strategies for Managed Care
Accreditation
The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). Pharmacists can earn a maximum of 3.75 contact hours of CPE credit by attending all CPE sessions during Specialty Connect (not including the satellite symposium held in conjunction with the conference). To obtain credit, pharmacists must attend a session in its entirety, participate in session-specific learning assessments, obtain a session-specific attendance code, complete a session evaluation, and record their participation online at https://amcplearn.org no later than 5:00 PM ET on Monday, May 28, 2018. No exceptions can be made after this date.
For additional information on AMCP’s continuing pharmacy education policies, please click here.
Statement of Commercial Support
This program was developed by the Academy of Managed Care Pharmacy. The educational activities are supported by independent educational grants from CSL Behring LLC, Novo Nordisk Inc. and Shire.
Meet the Moderator: Susan Winckler, RPh, Esq.
AMCP is proud to announce that our moderator for Specialty Connect will be Susan Winckler, RPh, Esq, President and Chief Risk Management Officer for Leavitt Partners, a health care intelligence firm. Founded by former HHS Secretary and EPA Administrator Michael O. Leavitt, LP advises senior executive teams about health care developments such as health insurance exchanges, Medicaid expansion, the conversion of fee-for-service payment to value-based payment, and helps clients navigate federal policy makers such as the Food and Drug Administration and the Centers for Medicare and Medicaid Services.
As President of Leavitt Partners Consulting, a national health care consulting firm, and Chief Risk Management Officer for the Leavitt Partners family of businesses, Ms. Winckler advises corporate executives on policy and business matters, such as Medicare/Medicaid, FDA practices and alternative payment models. As CEO of the Food & Drug Law Institute from 2009 – 2014, she provided attorneys, regulators, industry leaders and consumers with journals, meetings and a neutral forum for addressing domestic and global issues.
As FDA Chief of Staff from 2007-2009, Ms. Winckler managed the Commissioner’s office; served as his/her senior staff adviser; analyzed policies; and represented FDA before myriad government and external stakeholders. She simultaneously led FDA’s Offices of Legislation, External Relations, Public Affairs and Executive Secretariat.
As American Pharmacists Association (APhA) Vice President Policy/Communications and Staff Counsel, Ms. Winckler served as the association’s lead spokesperson and senior liaison to Congress, the executive branch, state associations and allied groups. Over the prior 9 years, she held several policy and practice-related jobs. Ms. Winckler earned a B.S. from the University of Iowa College of Pharmacy and her J.D. magna cum laude from Georgetown University Law Center. She is an APhA Fellow.